Latest clinical and nursing programme

Day 1

0930
Welcome & opening remarks
Mark Gilchrist - View Bio

Plenary - Can we tell you a story? Why we are here - an OPAT journey from the clinician and patient perspectives
0940
Fail better - the clinical story
Aisling Brown - View Bio
1000
Patient perspective - my experience of a complex treatment
Joseph Passingham
1010
Q&A

Plenary Session: Debate - Oral versus IV: Implications of the OVIVA Study
1030
Argument for early switching
1045
The alternative view including resistance, patients excluded from OVIVA study, impact of the microbiome, stewardship, side effects, ddis and oral therapies
Andrew Seaton - View Bio
1100
Questions from the floor

1130
Refreshments and networking

Parallel session one - Improving OPAT safety: Managing patient and service risk factors
1200
What makes a patient suitable or unsuitable for OPAT? How to assess
1220
How do we measure patient compliance? How far does this impact on outcomes?
1240
Managing treatment risks - how to reduce complications and initiate robust critical incident reporting procedures
1300
The competent OPAT team: developingskills and competence
Parallel session two - Free paper session
Chair: Sanjay Patel
1200
Selected from abstracts
1215
Selected from abstracts
1230
Selected from abstracts
1245
Selected from abstracts

1330
Lunch and poster viewing

Plenary sponsored symposium
1415
Cardiome

Keynote lecture
1500
OPAT and the UK Government agenda

Parallel session one - Pitching your OPAT business case to the Board: Exactly what is important?
1530
The importance of a clinical champions and an MDT approach
1550
Chief Executive Officer view - what we need to hear
1600
Chief Finance Officer view - talking finances
1610
Panel discussion with Q&A (Chair and speakers)
Parallel session two - Vascular Health and Vascular Access Issues
Chair: Andrew Jackson

1630
Refreshments and networking

Parallel session one - New and novel OPAT therapies and strategies
1700
Developing ambulatory OPAT in paediatric care
Lucy Hinds
1720
Treating acute bacterial skin and skin structure infections?
1740
Dalbavacin & OPAT - case series
Neil Ritchie, QEUH, Glasgow
Parallel session two - Vascular Health and Vascular Access Issues … continued

1820
Welcome drinks, networking and poster presentations
Day 2

0730
Breakfast refreshments

Plenary session: Clinical case studies: expert panel discussion
Chair: Sanjay Patel
0745
Case study 1
Eoghan de Barra - View Bio
0800
Case study 2
Eoghan de Barra - View Bio
0810
Case study 3
Gavin Barlow
0820
Case study 4
Gavin Barlow
0830
Expert panel discussion

Parallel session one - Treatments and pathways
0900
Learnings from the shop floor - dealing with infection in a high risk patient with difficult to understand personality
0925
Selected from abstracts
0950
Selected from abstracts
Parallel session two - Common vascular challenges
0900
tbc
0925
tbc
0950
tbc

Parallel session one - Respiratory disease and OPAT
1000
Tuberculosis
Helena White
1020
Bronchiectasis CF and non-CF
1040
Q&A/Panel discussion
Parallel session two - Workshop: Practical nursing aspects of OPAT
Chair: Carol Fry / Helen Green

1100
Refreshments and networking

1130
Sponsored symposium - Baxter

Plenary session - Driving the future of OPAT in the UK
Chair: Andrew Seaton
1215
Drug stability
Tim Hills - View Bio
1235
Update to the Good Practice Recommendations & Introduction of Competencies
Ann Chapman - View Bio
1300
Re-introduction of NORS and optimising medicine agenda
Mark Gilchrist - View Bio
1315
Whats in store for 2018?
Mark Gilchrist - View Bio

1320
Closing Remarks
Andrew Seaton - View Bio